Our results showed that the significantly changed neuronal subtype is GABAergic neurons, which suggested that the selection of GABA analog is a more niche-targeting strategy to treat epilepsy in this patient's family as well as in other patients with SCN1A loss-of-function. Here, SCN1A is linked to epilepsy.